The Global Reduction in Hepatitis B Disease Burden from Vaccination

[Guest guest]

The Global Reduction in Hepatitis B Disease Burden from Vaccination

ST Goldstein, F Zhou, SC Hadler, EE Mase, BP Bell, HS Margolis

Division of Viral Hepatitis

National Immunization Program, Centers for Disease Control and Prevention,

Atlanta, GA, USA

Background:

Few data are available regarding global hepatitis B virus (HBV)-related

morbidity and mortality and potential reduction in disease burden from

hepatitis B vaccination.

Methods:

HBV-related cirrhosis and hepatocellular carcinoma (HCC) mortality curves,

adjusted for background mortality, were used to calculate HBV-relate deaths

among persons with chronic HBV infection. Disease burden in the year 2000

(current burden) was estimated by applying the mortality curves to the 2000

population structure. To estimate the lifetime disease burden in the year

2000 birth cohort (future burden), a decision analysis was used to calculate

the age-specific risk of acquiring HBV infection, acute hepatitis B (illness

and death), and progression to chronic infection. Hepatitis B vaccination

impact was estimated from 3-dose vaccination coverage of infants, with and

without a birth dose of vaccine.

Results:

The estimated year 2000 HBV-related disease burden included 620,075 deaths,

580,545 (93%) from chronic infection (cirrhosis and HCC) and 39,530 (7%)

from acute hepatitis B. Over the lifetime of the year 2000 birth cohort, if

not vaccinated, there would be an estimated 64.8 million HBV infections, 9.7

million chronic infections, and 1.4 million deaths (1,340,327 [95%] from

chronic infection and 64,967 [5%] from acute hepatitis . Infections

acquired during the perinatal period, in early childhood (<5 years old), and

=5 years of age would account for 21 %, 48%, and 31 % of deaths,

respectively. Routine infant hepatitis B vaccination, with 90% 3-dose

coverage and no birth dose, would prevent 68% of HBV-related deaths. The

reduction in HBV-related deaths would increase to 84% if the 90% 3-dose

vaccination coverage included a dose of vaccine administered at birth.

Conclusion:

Globally, most HBV-related deaths result from the chronic sequelae of

infection acquired in the perinatal and early childhood periods. Inclusion

of hepatitis B vaccine in national infant immunization programs would

prevent >80% of HBV-related deaths.

http://www.hcvadvocate.org/news/reports/International_Symposium.html

[Guest guest]

The Global Reduction in Hepatitis B Disease Burden from Vaccination

ST Goldstein, F Zhou, SC Hadler, EE Mase, BP Bell, HS Margolis

Division of Viral Hepatitis

National Immunization Program, Centers for Disease Control and Prevention,

Atlanta, GA, USA

Background:

Few data are available regarding global hepatitis B virus (HBV)-related

morbidity and mortality and potential reduction in disease burden from

hepatitis B vaccination.

Methods:

HBV-related cirrhosis and hepatocellular carcinoma (HCC) mortality curves,

adjusted for background mortality, were used to calculate HBV-relate deaths

among persons with chronic HBV infection. Disease burden in the year 2000

(current burden) was estimated by applying the mortality curves to the 2000

population structure. To estimate the lifetime disease burden in the year

2000 birth cohort (future burden), a decision analysis was used to calculate

the age-specific risk of acquiring HBV infection, acute hepatitis B (illness

and death), and progression to chronic infection. Hepatitis B vaccination

impact was estimated from 3-dose vaccination coverage of infants, with and

without a birth dose of vaccine.

Results:

The estimated year 2000 HBV-related disease burden included 620,075 deaths,

580,545 (93%) from chronic infection (cirrhosis and HCC) and 39,530 (7%)

from acute hepatitis B. Over the lifetime of the year 2000 birth cohort, if

not vaccinated, there would be an estimated 64.8 million HBV infections, 9.7

million chronic infections, and 1.4 million deaths (1,340,327 [95%] from

chronic infection and 64,967 [5%] from acute hepatitis . Infections

acquired during the perinatal period, in early childhood (<5 years old), and

=5 years of age would account for 21 %, 48%, and 31 % of deaths,

respectively. Routine infant hepatitis B vaccination, with 90% 3-dose

coverage and no birth dose, would prevent 68% of HBV-related deaths. The

reduction in HBV-related deaths would increase to 84% if the 90% 3-dose

vaccination coverage included a dose of vaccine administered at birth.

Conclusion:

Globally, most HBV-related deaths result from the chronic sequelae of

infection acquired in the perinatal and early childhood periods. Inclusion

of hepatitis B vaccine in national infant immunization programs would

prevent >80% of HBV-related deaths.

http://www.hcvadvocate.org/news/reports/International_Symposium.html

[Guest guest]

The Global Reduction in Hepatitis B Disease Burden from Vaccination

ST Goldstein, F Zhou, SC Hadler, EE Mase, BP Bell, HS Margolis

Division of Viral Hepatitis

National Immunization Program, Centers for Disease Control and Prevention,

Atlanta, GA, USA

Background:

Few data are available regarding global hepatitis B virus (HBV)-related

morbidity and mortality and potential reduction in disease burden from

hepatitis B vaccination.

Methods:

HBV-related cirrhosis and hepatocellular carcinoma (HCC) mortality curves,

adjusted for background mortality, were used to calculate HBV-relate deaths

among persons with chronic HBV infection. Disease burden in the year 2000

(current burden) was estimated by applying the mortality curves to the 2000

population structure. To estimate the lifetime disease burden in the year

2000 birth cohort (future burden), a decision analysis was used to calculate

the age-specific risk of acquiring HBV infection, acute hepatitis B (illness

and death), and progression to chronic infection. Hepatitis B vaccination

impact was estimated from 3-dose vaccination coverage of infants, with and

without a birth dose of vaccine.

Results:

The estimated year 2000 HBV-related disease burden included 620,075 deaths,

580,545 (93%) from chronic infection (cirrhosis and HCC) and 39,530 (7%)

from acute hepatitis B. Over the lifetime of the year 2000 birth cohort, if

not vaccinated, there would be an estimated 64.8 million HBV infections, 9.7

million chronic infections, and 1.4 million deaths (1,340,327 [95%] from

chronic infection and 64,967 [5%] from acute hepatitis . Infections

acquired during the perinatal period, in early childhood (<5 years old), and

=5 years of age would account for 21 %, 48%, and 31 % of deaths,

respectively. Routine infant hepatitis B vaccination, with 90% 3-dose

coverage and no birth dose, would prevent 68% of HBV-related deaths. The

reduction in HBV-related deaths would increase to 84% if the 90% 3-dose

vaccination coverage included a dose of vaccine administered at birth.

Conclusion:

Globally, most HBV-related deaths result from the chronic sequelae of

infection acquired in the perinatal and early childhood periods. Inclusion

of hepatitis B vaccine in national infant immunization programs would

prevent >80% of HBV-related deaths.

http://www.hcvadvocate.org/news/reports/International_Symposium.html

[Guest guest]

The Global Reduction in Hepatitis B Disease Burden from Vaccination

ST Goldstein, F Zhou, SC Hadler, EE Mase, BP Bell, HS Margolis

Division of Viral Hepatitis

National Immunization Program, Centers for Disease Control and Prevention,

Atlanta, GA, USA

Background:

Few data are available regarding global hepatitis B virus (HBV)-related

morbidity and mortality and potential reduction in disease burden from

hepatitis B vaccination.

Methods:

HBV-related cirrhosis and hepatocellular carcinoma (HCC) mortality curves,

adjusted for background mortality, were used to calculate HBV-relate deaths

among persons with chronic HBV infection. Disease burden in the year 2000

(current burden) was estimated by applying the mortality curves to the 2000

population structure. To estimate the lifetime disease burden in the year

2000 birth cohort (future burden), a decision analysis was used to calculate

the age-specific risk of acquiring HBV infection, acute hepatitis B (illness

and death), and progression to chronic infection. Hepatitis B vaccination

impact was estimated from 3-dose vaccination coverage of infants, with and

without a birth dose of vaccine.

Results:

The estimated year 2000 HBV-related disease burden included 620,075 deaths,

580,545 (93%) from chronic infection (cirrhosis and HCC) and 39,530 (7%)

from acute hepatitis B. Over the lifetime of the year 2000 birth cohort, if

not vaccinated, there would be an estimated 64.8 million HBV infections, 9.7

million chronic infections, and 1.4 million deaths (1,340,327 [95%] from

chronic infection and 64,967 [5%] from acute hepatitis . Infections

acquired during the perinatal period, in early childhood (<5 years old), and

=5 years of age would account for 21 %, 48%, and 31 % of deaths,

respectively. Routine infant hepatitis B vaccination, with 90% 3-dose

coverage and no birth dose, would prevent 68% of HBV-related deaths. The

reduction in HBV-related deaths would increase to 84% if the 90% 3-dose

vaccination coverage included a dose of vaccine administered at birth.

Conclusion:

Globally, most HBV-related deaths result from the chronic sequelae of

infection acquired in the perinatal and early childhood periods. Inclusion

of hepatitis B vaccine in national infant immunization programs would

prevent >80% of HBV-related deaths.

http://www.hcvadvocate.org/news/reports/International_Symposium.html